The prevalence of autism spectrum disorder (ASD) among children in the United States has risen dramatically over the past two decades. In 2022, an estimated 32.2 out of every 1,000 8-year-old children were identified with ASD, marking a nearly fivefold increase from the rate of 6.7 per 1,000 children in 2000. This significant upward trend underscores the growing importance of understanding and addressing ASD in American society. Gender disparities in autism diagnosis The increase in ASD prevalence is not uniform across genders. From 2016 to 2019, male children were nearly four times more likely to be diagnosed with ASD than their female counterparts. Approximately 4.8 percent of boys aged 3 to 17 years had received an ASD diagnosis at some point in their lives, compared to only 1.3 percent of girls in the same age group. This substantial gender gap highlights the need for further research into potential biological and social factors influencing ASD diagnosis rates. Racial and ethnic variations in autism prevalence Autism prevalence also varies across racial and ethnic groups. Data from 2016 to 2019 show that non-Hispanic white children aged 3 to 17 years had an ASD prevalence of 2.9 percent, while around 3.5 percent of Hispanic children had ASD. While this statistic provides insight, it is essential to consider potential disparities in diagnosis and access to services among different racial and ethnic communities. Further research and targeted interventions may be necessary to ensure equitable identification and support for children with ASD across all populations.

This data table provides a collection of information from peer-reviewed autism prevalence studies. Information reported from each study includes the autism prevalence estimate and additional study characteristics (e.g., case ascertainment and criteria). A PubMed search was conducted to identify studies published at any time through September 2020 using the search terms: autism (title/abstract) OR autistic (title/abstract) AND prevalence (title/abstract). Data were abstracted and included if the study fulfilled the following criteria: • The study was published in English; • The study produced at least one autism prevalence estimate; and • The study was population-based (any age range) within a defined geographic area.

In 2021, it was estimated that ****percent of the total global population suffered from autism spectrum disorders. This statistic depicts the percentage of the global population with autism spectrum disorders in 2021, by region.

This statistic displays the prevalence rate of autism spectrum disorders in Italy from 2010 to 2017. According to data, the rate slightly decreased over the period of consideration. As of 2017, among the Italian population about *** out of 100,000 individuals suffered from some autism spectrum disorder.

This report presents a new estimate of the prevalence of autism among adults aged 18 years and over. This was derived using data from the 2007 Adult Psychiatric Morbidity Survey (APMS 2007) in combination with data from a new study of the prevalence of autism among adults with learning disabilities, who are a key group to study because they could not take part in the APMS 2007 and have been found to have an increased risk of autism. The study was based on adults with learning disabilities living in private households and communal care establishments in Leicestershire, Lambeth and Sheffield. Whilst the study comprised a relatively small sample with limited geographical coverage and did not include the institutional population, it did include two non-mutually exclusive populations (people in communal care establishments and people with learning disabilities) which were not covered by the APMS 2007. The study demonstrates that autism is common among people with a learning disability and, in taking these into account, at 1.1 per cent nationally is slightly higher than the previous estimate of 1.0 per cent in the APMS 2007. Sensitivity analysis showed that the estimates for national prevalence produced by this study were relatively insensitive to inaccuracies caused by the limitations.

ASD prevalence was defined by parent-reported doctor diagnoses and estimated at the county level by aggregating predicted child-level prevalence using population-based post-stratification weights.

This statistic shows the prevalence rate of autism spectrum disorders in Italy in 2017, by age group. According to the estimates, in the age group including kids aged five to nine roughly *** children out of 100,000 population, were suffering from autism spectrum disorders.

Structural variation is thought to play a major etiological role in the development of autism spectrum disorders (ASDs), and numerous studies documenting the relevance of copy number variants (CNVs) in ASD have been published since 2006. To determine if large ASD families harbor high-impact CNVs that may have broader impact in the general ASD population, we used the Affymetrix genome-wide human SNP array 6.0 to identify 153 putative autism-specific CNVs present in 55 individuals with ASD from 9 multiplex ASD pedigrees. To evaluate the actual prevalence of these CNVs as well as 185 CNVs reportedly associated with ASD from published studies many of which are insufficiently powered, we designed a custom Illumina array and used it to interrogate these CNVs in 3,000 ASD cases and 6,000 controls. Additional single nucleotide variants (SNVs) on the array identified 25 CNVs that we did not detect in our family studies at the standard SNP array resolution. After molecular validation, our results demonstrated that 15 CNVs identified in high-risk ASD families also were found in two or more ASD cases with odds ratios greater than 2.0, strengthening their support as ASD risk variants. In addition, of the 25 CNVs identified using SNV probes on our custom array, 9 also had odds ratios greater than 2.0, suggesting that these CNVs also are ASD risk variants. Eighteen of the validated CNVs have not been reported previously in individuals with ASD and three have only been observed once. Finally, we confirmed the association of 31 of 185 published ASD-associated CNVs in our dataset with odds ratios greater than 2.0, suggesting they may be of clinical relevance in the evaluation of children with ASDs. Taken together, these data provide strong support for the existence and application of high-impact CNVs in the clinical genetic evaluation of children with ASD.

Input datasets on Ohio Birth and Autism will not be made accessible to the public due to the fact that they include individual-level data with PII. Output data are all available in tabulated form within the published manuscript. This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Input data can be obtained from Applications from owners of the data (Children's Hospital and Ohio Department of Health). The tabulated output data is found in the manuscript. Format: Input datasets on Ohio Birth and Autism will not be made accessible to the public due to the fact that they include individual-level data with PII. Output data are all available in tabulated form within the published manuscript (e.g., results of regression models, measures of central tendency, population characteristics, etc.). This dataset is associated with the following publication: Kaufman, J., M. Wright, G. Rice, N. Connolly, K. Bowers, and J. Anixt. AMBIENT OZONE AND FINE PARTICULATE MATTER EXPOSURES AND AUTISM SPECTRUM DISORDER IN METROPOLITAN CINCINNATI, OHIO. ENVIRONMENTAL RESEARCH. Elsevier B.V., Amsterdam, NETHERLANDS, 171: 218-227, (2019).

In 2017, the highest DALY rates attributed to autism spectrum disorders was seen in Bihar, categorized as a low SDI state with **. DALYs or disability adjusted life years is a metric used to quantify the overall disease burden which is the number of years that are lost as a result of ill-health, disability or premature death. Furthermore, in Arunachal Pradesh, a medium SDI state also recorded a DALY rate of **. By contrast, the lowest DALY rate relative to autism spectrum disorders was seen in Himachal Pradesh, which is a high SDI state with **.

Background: Whilst cannabis is known to be toxic to brain function and brain development in many respects it is not known if its increasing availability is associated with the rising US autism rates, whether this contribution is sufficient to effect overall trends and if its effects persist after controlling for other major covariates.

Methods: Longitudinal epidemiological study using national autism census data from the US Department of Education Individuals with Disabilities Act (IDEA) 1991-2011 and nationally representative drug exposure (cigarettes, alcohol, analgesic, and cocaine abuse, and cannabis use monthly, daily and in pregnancy) datasets from National Survey of Drug Use and Health and US Census (income and ethnicity) and CDC Wonder population and birth data. Geotemporospatial and causal inference analysis conducted in R.

Results: 266,950 autistic of a population of 40,119,464 eight year olds 1994-2011. At the national level after adjustment daily cannabis use was significantly related (β-estimate=4.37 (95%C.I. 4.06-4.68), P<2.2x10-16) as was cannabis exposure in the first trimester of pregnancy (β-estimate=0.12 (0.08-0.16), P=1.7x10-12). At the state level following adjustment cannabis use was significant (from β-estimate=8.41 (3.08-13.74), P=0.002); after adjustment for varying cannabis exposure by ethnicity and other covariates (from β-estimate=10.88 (5.97-15.79), P=1.4x10-5). Cannabigerol (from β-estimate=-13.77 (-19.41—8.13), P = 1.8x10-6) and Δ9-tetrahydrocannabinol (from β-estimate=1.96 (0.88-3.04), P=4x10-4) were also significant. Geospatial state-level modelling showed an exponential relationship between ASMR and both Δ9-tetrahydrocannabinol and cannabigerol exposure; effect size calculations reflected this exponentiation. Exponential coefficients for the relationship between modelled ASMR and THC- and cannabigerol- exposure were 7.053 (6.39-7.71) and 185.334 (167.88-202.79; both P<2.0x10-7).

In inverse probability-weighted robust generalized linear models ethnic cannabis exposure (from β-estimate=3.64 (2.94-4.34), P=5.9x10-13) and cannabis independently (β-estimate=1.08 (0.63-1.54), P=2.9x10-5) were significant. High eValues in geospatial models indicated that uncontrolled confounding did not explain these findings. Therefore the demonstrated relationship satified the criteria of causal inference. Dichotomized legal status was geospatiotemporally linked with elevated ASMR.

Conclusions: Data show cannabis use is associated with ASMR, is powerful enough to affect overall trends, and persists after controlling for other major drug, socioeconomic, and ethnic-related covariates. Selected cannabinoids are exponentially associated with ASMR. The cannabis-autism relationship satisfies criteria of causal inference.

This dataset is no longer updated as of April 2023.

Basic Metadata Note: Condition is a new addition to 2017. *Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.

**Blank Cells: Rates not calculated for fewer than 5 events. Rates not calculated in cases where zip code is unknown.

***API: Asian/Pacific Islander. ***AIAN: American Indian/Alaska Native.

Prepared by: County of San Diego, Health & Human Services Agency, Public Health Services, Community Health Statistics Unit, 2019.

Code Source: ICD-9CM - AHRQ HCUP CCS v2015. ICD-10CM - AHRQ HCUP CCS v2018. ICD-10 Mortality - California Department of Public Health, Group Cause of Death Codes 2013; NHCS ICD-10 2e-v1 2017.

Data Guide, Dictionary, and Codebook: https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/CHS/Community%20Profiles/Public%20Health%20Services%20Codebook_Data%20Guide_Metadata_10.2.19.xlsx

As of 2023, almost ***** percent of those living in the state of West Virginia had a cognitive disability, such as Down syndrome, autism, or dementia. This statistic shows the percentage of people in the U.S. who had a cognitive disability as of 2023, by state.

The PPV and NPV reported when using two different prevalence values, one for the general population in the USA (1/68), and the other for the high-risk population (18.7%).

The global market for the diagnosis and treatment of Autism Spectrum Disorder (ASD) is experiencing robust growth, driven by a confluence of increasing awareness, improved diagnostic tools, and advancements in therapeutic interventions. With an estimated market size of approximately USD 6,500 million in 2025, the sector is projected to expand at a Compound Annual Growth Rate (CAGR) of around 7.5% through 2033. This significant expansion is fueled by rising prevalence rates, greater parental advocacy, and a growing emphasis on early intervention, which are critical for improving outcomes for individuals with ASD. The market is also benefiting from increased government funding for research and support services, as well as a more comprehensive understanding of the diverse needs of the ASD population. Furthermore, the development of innovative diagnostic technologies and personalized treatment approaches, including behavioral therapies, pharmacotherapy, and emerging gene-based therapies, are key drivers contributing to the market's upward trajectory. The increasing demand for specialized care across various settings, from hospitals and clinics to home-based services, underscores the comprehensive nature of the market's evolution. The market landscape for ASD diagnosis and treatment is characterized by a dynamic interplay of established pharmaceutical giants and specialized biotechnology firms. Key players like Otsuka, AstraZeneca, Pfizer, and Eli Lilly are actively involved in developing and marketing pharmacological treatments, while companies such as Behavior Analysis, SynapDx, and Autism Therapeutics are at the forefront of diagnostic tools and specialized therapies. The market is segmented by application (hospitals, clinics, and others) and by type (adults and children), with the pediatric segment currently dominating due to the emphasis on early diagnosis and intervention. Geographically, North America, particularly the United States, leads the market, owing to high prevalence rates, advanced healthcare infrastructure, and substantial investment in research and development. Europe also holds a significant share, driven by strong healthcare systems and increasing awareness. The Asia Pacific region is poised for substantial growth, fueled by a rising population, improving healthcare access, and growing diagnostic capabilities. Despite the promising outlook, challenges such as diagnostic delays in certain regions, limited access to specialized therapies in underserved communities, and the high cost of some advanced treatments present ongoing hurdles that the industry is working to address. This report provides an in-depth analysis of the global market for the diagnosis and treatment of Autism Spectrum Disorder (ASD). Spanning a study period from 2019 to 2033, with a base and estimated year of 2025, this research offers valuable insights into market dynamics, key players, and future trends. The report is designed for stakeholders seeking a granular understanding of this rapidly evolving sector, with an estimated market size of over $20,000 million by 2025.

ID, intellectual disability; ASD, autism spectrum disorder; Mild ID, Mild or moderate intellectual disability; Severe ID, Severe or profound intellectual disability; Down, Down syndrome.Demographic and psychiatric characteristics of the study population by number and percentage of maternal group.

The aim of this publication is to provide information about the key differences in healthcare between people with a learning disability and those without. It contains aggregated data on key health issues for people who are recorded by their GP as having a learning disability, and comparative data about a control group who are not recorded by their GP as having a learning disability. Six new indicators were introduced in the 2022-23 reporting year for patients with and without a recorded learning disability. These relate to: • Patients with an eating disorder • Patients with both an eating disorder and autism diagnosis • Patients with a diagnosis of autism who are currently treated with antidepressants More information on these changes can be found in the Data Quality section of this publication. Data has been collected from participating practices using EMIS and Cegedim Healthcare Systems GP systems.

Psychiatric comorbidity in autism spectrum disorder (ASD) is a subject of critical scientific importance, affecting the quality of life, prognosis, and functional outcomes. The prevalence of psychiatric disorders vary considerably according to variables such as index subject characteristics, study setting, sampling frame, diagnostic methods used, as well as country of geographic origin. To date, most studies comprise clinical or treatment referral samples in tertiary care or subjects enrolled in clinical trials and genetic cohort collections. Such samples carry the potential for overestimation of both the frequency and severity of psychiatric comorbidity. A systematic literature search was performed using PubMed and Web of Science databases restricted to population-based study publications in the English between May 1, 2015, and May 31, 2020. A comprehensive keyword list was generated to investigate co-occurrence of psychiatric disorders in children and adolescents with ASD. A wide range of DSM-5 based disorders such as anxiety, mood, ADHD, intellectual disability/intellectual developmental disorder, eating/feeding, gender dysphoria and sleep-wake disorders were assessed. Initial search revealed a total of 1674 articles after removal of duplicates. Two independent researchers conducted a parallel-blinded screening process to identify the eligible studies based on titles and abstracts; 39 studies were analyzed in the current review. The main findings show prevalence estimates of 22.9% (95% CI: 17.7- 29.2) for intellectual disability; 26.2% (22-31) for attention-deficit hyperactivity disorder; 11.1% (8.6-14.1) for anxiety disorders; 19.7% (11.9-30.7) for sleep disorders; 7% (5.2- 9.3) for disruptive disorders; 2% (1.3- 3.1) for bipolar disorders; 2.7% (1.8- 4.2) for depression; 1.8% (0.4–8.7) for obsessive-compulsive disorder; and 0.6% (0.3–1.1) for psychosis. Psychiatric comorbidity in population-based studies is lower than in clinical and referred samples. However, our results also indicate that the frequency of psychiatric comorbidity in children and adolescents with ASD in the population context is considerable, without the influence of referral bias implicit in clinical and treatment samples. There is a need for better targeted diagnostic tools to detect psychiatric comorbidity in children and youth in future population-based studies, as an essential component in providing care as well as new insights into the nature and mechanisms of its underlying associations.Systematic Review Registration[https://www.crd.york.ac.uk/prospero/], identifier [CRD42021234464].

The global Autism Spectrum Disorder (ASD) Diagnostics market is projected to reach a valuation of USD X million by 2033, exhibiting a CAGR of XX% over the forecast period 2025-2033. Rising prevalence of ASD, increasing awareness of the disorder, and technological advancements in diagnostic tools are driving the market growth. Additionally, government initiatives and support for early detection and diagnosis of ASD are further boosting the market. However, the high cost of genetic testing and the lack of skilled healthcare professionals in certain regions may pose challenges to the market's growth. The market is segmented based on application, type, and region. By application, the market is divided into early diagnosis and screening, genetic testing, and neuroimaging. By type, the market is classified into genetic tests (karyotyping, chromosomal microarray, single-gene sequencing), neuroimaging tests (MRI, EEG, PET), and behavioral assessments. Regionally, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America currently holds a significant market share due to the high prevalence of ASD and advanced healthcare infrastructure. However, the Asia Pacific region is expected to witness the fastest growth rate during the forecast period, owing to increasing awareness, government initiatives, and a growing population.